on their shared immune targets (Table 4).
Approximately half of the patients (52.0%) were prescribed a biologic that inhibits IL-12/23 and IL23 at baseline, and the other half were prescribed a biologic that inhibits either IL-17 (31.0%) or TNFα (17.0%) (Table 4). Ten patients switched biologics, with 4 of those patients switching prior to the follow-up study visit. The biologic dosing frequency was reduced to every 24 weeks at follow-up for 1 patient; 2 patients discontinued biologic treatment entirely (1 prior to follow-up, and the other at followup). Concomitant psoriatic treatments including apremilast, acitretin, and narrowband ultraviolet B (UVB) phototherapy were prescribed to 5 patients either before or at follow-up. One patient discontinued use of acitretin prior to follow-up but maintained their biologic regimen throughout the study. The time interval between baseline and follow-up visits ranged between 4 and 12 months across all patients, with a mean of 6.7 months
